Yangchun Du, PhD
- 5Articles
- 47.5KReads1
- 2015–2020Active
- 24Collaborators
- 156Citations2
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
About
Yangchun Du, PhD, has contributed to research on schizophrenia and schizoaffective disorders, with a focus on the clinical application and long-term outcomes of aripiprazole lauroxil treatment. Publications include studies on the safety, efficacy, and metabolic effects of aripiprazole lauroxil in both acute and extended treatment phases. Du's work spans randomized controlled trials and extension studies examining therapeutic durability and patient transition from inpatient to outpatient care. Frequent collaborators include Peter J. Weiden, Robert Risinger, Amy Claxton, Anjana Bose, and Bernard L. Silverman.
Publications
Long-Term Safety of Aripiprazole Lauroxil
August 18, 2020
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
